Anlotinib is an oral novel multitargeted TKI that inhibits angiogenesis and tumor cell proliferation by targeting VEGFR, platelet‐derived growth factor receptor (PDGFR), fibroblast growth factor receptors (FGFRs), tyrosine kinase (c‐Kit).7 The gene discussed is KIT; the disease is neoplasm.